Abstract:Vascular endothelial growth factor (VEGF) has been shown to play an important role in tumor growth and progression. However, the clinical implications of VEGF expression in ovarian tumors are not fully understood. We therefore investigated the serum level of VEGF in patients with ovarian tumors and explored the potential use of VEGF as a tumor marker for diagnosis, treatment and prognosis of human ovarian cancer. The serum VEGF (sVEGF) levels in 120 patients with ovarian carcinoma, 25 patients with benign ovarian tumor and 90 healthy female blood donors were measured by an enzyme-linked immunosorbent assay in this study. We also determined the levels of sVEGF in patients with epithelial ovarian cancer before and after surgery. Our results showed that: (i) ovarian cancer patients had significantly higher levels of sVEGF compared to those of patients with benign ovarian tumor or those of healthy individuals. As a cut-off at 100 pg/ml, the sensitivity and specificity of sVEGF levels for diagnosing ovarian carcinoma were 77.1% and 87%, respectively. (ii) sVEGF levels were markedly elevated in patients with advanced stage or poorly-differentiated ovarian cancer, as well as in those with more ascites (>500 ml), as compared to patients with early stage and well-differentiated ovarian cancer, or those with less ascites (<500 ml). However, there was no significant difference in sVEGF levels among different pathological subtypes of ovarian carcinoma. (iii) The post-operative sVEGF levels were significantly lower than the pre-operative sVEGF levels. (iv) We measured significantly higher levels of sVEGF in patients with metastasis as compared to patients lacking metastasis. Lastly (v) the average survival-time in patients with higher levels of sVEGF (>100 pg/ml) was 28 months, while the average survival-time in patients with lower levels of sVEGF (<100 pg/ml) was 35 months, indicating that the elevations in sVEGF level are correlated with patient survival and tumor metastasis in ovarian carcinoma. These data suggest that VEGF may be a useful serological biomarker for clinical diagnosis and prognosis of ovarian cancer, for follow-up of ovarian tumor metastasis and for monitoring the efficacy of therapy in patients with ovarian carcinomas.

The Expression of VEGF and Dll4/Notch Pathway Molecules in Ovarian Cancer

Expression and clinical significance of P16, P15,and VEGF proteins in primary epithelial ovarian carcinoma

[Expressions of VEGF/VEGFRs and Activation of STATs in Ovarian Carcinoma].

[Expression of Mrna Isoforms of Vascular Endothelial Growth Factor in Ovarian Carcinoma]

VEGF, VEGFRs Expressions and Activated STATs in Ovarian Epithelial Carcinoma

Prognostic Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Carcinoma of Ampulla of Vater.

The expression of VEGF in human ovarian cancer

Expression and prognostic significance of VEGF and its receptor VEGFR1 and VEGFR2 in epithelial ovarian cancer

Expression of VEGF‐D in Epithelial Ovarian Cancer and Its Relationship to Lymphatic Metastasis

[Expression of Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor-3 and Nm23-H1 in Oral Squamous Cell Carcinoma].

The Expression and Clinical Significance of Vascular Endothelial Growth Factor-C in Gastric Cancer Tissues

Relationship of Vascular Endothelial Growth Factor A Expression in Lymphangiogenesis and Angiogenesis

Expression of CD44V6,VEGF and nm23-H1 on Ovarian Cancerous Tissue and Its Clinical Significance

Correlation of Serum VEGF Levels with Clinical Stage, Therapy Efficacy, Tumor Metastasis and Patient Survival in Ovarian Cancer.

A VEGF-dependent Gene Signature Enriched in Mesenchymal Ovarian Cancer Predicts Patient Prognosis

Expression and clinical significance of MMP-2 and VEGF protein in epithelial ovarian tumors

Relation Between the Expression of Hypoxia Inducible Factor-1Α and Angiogenesis in Ovarian Cancer Using Tissue Microarray

Expression of Endocrine Gland-Derived Vascular Endothelial Growth Factor in Ovarian Carcinoma.

Expressions of LN, MMP and Microvessel Density in Ovarian Tumors

Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC)

Functional Significance of VEGF-a in Human Ovarian Carcinoma: Role in Vasculogenic Mimicry.